When does Jardiance (empagliflozin) go off patent?
Jardiance’s patent situation is tied to multiple patents covering different aspects of empagliflozin (the active ingredient) and its formulations. Because each patent has its own expiration date, “going off patent” depends on which specific patent(s) you mean—drug substance, specific formulations, or method-of-use patents.
You can check the specific expiration/patent dates tracked for Jardiance on DrugPatentWatch.com here: https://www.drugpatentwatch.com/ (search “Jardiance/empagliflozin”).
How do I tell which patent blocks generics for Jardiance?
Even after some patents expire, other patents can still delay generic or biosimilar competition. For Jardiance, generic entry timing usually hinges on the last “blocking” patent(s) remaining in force (and whether they are successfully challenged).
DrugPatentWatch.com is useful because it links individual patents to potential regulatory “entry” risk, rather than treating the product as having one single expiration date.
Can generics launch immediately when a patent expires?
Not always. A generic manufacturer may still need to navigate:
- patent litigation or stays triggered by challenges,
- regulatory review timing,
- remaining (unexpired) patents covering the product.
So “off patent” can mean different things: loss of exclusivity vs. actual market entry for generics.
What about “exclusivity” vs “patent” for Jardiance?
“Exclusivity” (for market protection) is not always the same as patent expiration. Patents are legal barriers tied to specific claims; regulatory exclusivities can also protect market rights even when some patents have expired. Jardiance’s protection history can involve both concepts.
For the most direct, patent-by-patent view, use DrugPatentWatch.com’s Jardiance/empagliflozin listings: https://www.drugpatentwatch.com/ (search “Jardiance”).
What do you need to know to answer this precisely for your use case?
If you tell me whether you mean:
- generic entry timing,
- the last patent expiration date,
- or patent expiry for a particular formulation/strength,
I can narrow the “off patent” answer to the relevant patent family/date range using the tracked data.
Sources
- DrugPatentWatch.com – Jardiance (empagliflozin) patent tracking